- Home
- SVII vs BDSX Comparison
SVII vs BDSX Comparison
Compare SVII & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVII
- BDSX
- Stock Information
- Founded
- SVII 2021
- BDSX 2005
- Country
- SVII United States
- BDSX United States
- Employees
- SVII N/A
- BDSX N/A
- Industry
- SVII Blank Checks
- BDSX Precision Instruments
- Sector
- SVII Finance
- BDSX Health Care
- Exchange
- SVII Nasdaq
- BDSX Nasdaq
- Market Cap
- SVII 248.9M
- BDSX 245.3M
- IPO Year
- SVII 2022
- BDSX 2020
- Fundamental
- Price
- SVII $11.33
- BDSX $1.69
- Analyst Decision
- SVII
- BDSX Strong Buy
- Analyst Count
- SVII 0
- BDSX 4
- Target Price
- SVII N/A
- BDSX $3.08
- AVG Volume (30 Days)
- SVII 17.4K
- BDSX 247.5K
- Earning Date
- SVII 01-01-0001
- BDSX 11-05-2024
- Dividend Yield
- SVII N/A
- BDSX N/A
- EPS Growth
- SVII 36.87
- BDSX N/A
- EPS
- SVII 0.37
- BDSX N/A
- Revenue
- SVII N/A
- BDSX $60,902,000.00
- Revenue This Year
- SVII N/A
- BDSX $48.06
- Revenue Next Year
- SVII N/A
- BDSX $29.97
- P/E Ratio
- SVII $30.61
- BDSX N/A
- Revenue Growth
- SVII N/A
- BDSX 46.25
- 52 Week Low
- SVII $10.72
- BDSX $1.15
- 52 Week High
- SVII $11.33
- BDSX $2.21
- Technical
- Relative Strength Index (RSI)
- SVII 77.35
- BDSX 46.06
- Support Level
- SVII $11.20
- BDSX $1.62
- Resistance Level
- SVII $11.23
- BDSX $1.71
- Average True Range (ATR)
- SVII 0.01
- BDSX 0.06
- MACD
- SVII 0.00
- BDSX -0.00
- Stochastic Oscillator
- SVII 100.00
- BDSX 47.62
About SVII Spring Valley Acquisition Corp. II
Spring Valley Acquisition Corp II is a blank check company.
About BDSX Biodesix Inc.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.